A Multi-Center, Unblinded, Single-Arm Study to Evaluate Sex Differences in the Acute Effects of PL-3994 on Myocardial cGMP Enhancement and Hemodynamics in Heart Failure With Preserved Ejection Fraction
Latest Information Update: 19 Dec 2025
At a glance
- Drugs PL 3994 (Primary)
- Indications Heart failure
- Focus Adverse reactions; Therapeutic Use
- Sponsors Palatin Technologies
Most Recent Events
- 15 Dec 2025 Actual Primary Completion date changed to 8 Dec 2023
- 15 Dec 2025 Status changed from recruiting to discontinued. (Study cancelled after Part A. Enrollment taking too long.)
- 13 Dec 2021 Planned End Date changed from 30 Nov 2021 to 31 Mar 2023.